This company listing is no longer active
IMU Stock Overview
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ImmunoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.17 |
| 52 Week High | US$6.67 |
| 52 Week Low | US$3.05 |
| Beta | 1.06 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 2.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 41.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 0.4% |
| 1Y | 2.2% | -11.8% | 13.1% |
Return vs Industry: IMU exceeded the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: IMU underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| IMU volatility | |
|---|---|
| IMU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: IMU has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 106 | Mark Enyedy | www.immunogen.com |
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate.
ImmunoGen, Inc. Fundamentals Summary
| IMU fundamental statistics | |
|---|---|
| Market cap | €1.06b |
| Earnings (TTM) | -€193.57m |
| Revenue (TTM) | €92.03m |
11.6x
P/S Ratio-5.5x
P/E RatioIs IMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMU income statement (TTM) | |
|---|---|
| Revenue | US$95.61m |
| Cost of Revenue | US$203.85m |
| Gross Profit | -US$108.25m |
| Other Expenses | US$92.85m |
| Earnings | -US$201.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | -113.22% |
| Net Profit Margin | -210.33% |
| Debt/Equity Ratio | 0% |
How did IMU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/16 13:35 |
| End of Day Share Price | 2022/08/19 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmunoGen, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Wang | Brean Capital |
| John Newman | Canaccord Genuity |
| Mara Goldstein | Cantor Fitzgerald & Co. |